In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis

Toxicological Sciences

Volumn 131, Issue 1, 2013, Pages 40-55

  Kleinstreuer, Nicole C ^a   Dix, David J ^a   Houck, Keith A ^a   Kavlock, Robert J ^a   Knudsen, Thomas B ^a   Martin, Matthew T ^a   Paul, Katie B ^b   Reif, David M ^a   Crofton, Kevin M ^b   Hamilton, Kerry ^c   Hunter, Ronald ^c   Shah, Imran ^a   Judson, Richard S ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c AMERICAN PUBLIC HEALTH ASSOCIATION   (United States)

Author keywords

Bioinformatics.; Cancer hallmarks; Carcinogenesis; In vitro and alternatives; Predictive toxicology

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 1A1; INTERLEUKIN 8; MULTIDRUG RESISTANCE PROTEIN 1; OPIATE RECEPTOR; OPIOID RECEPTOR LIKE 1; ORGANIC ANION TRANSPORTER 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHODIESTERASE; PHOSPHODIESTERASE 5A; TUMOR MARKER; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ANGIOGENESIS; ANIMAL GENETICS; APOPTOSIS; ARTICLE; CANCER GROWTH; CHEMICAL CARCINOGENESIS; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE MODEL; ENERGY METABOLISM; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; LIVER CANCER; NONHUMAN; RODENT; SCORING SYSTEM; SIGNAL TRANSDUCTION; TOXICITY TESTING;

ANIMALS; CARCINOGENICITY TESTS; CARCINOGENS; DATABASES, FACTUAL; ENDPOINT DETERMINATION; HIGH-THROUGHPUT SCREENING ASSAYS; MICE; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RATS; SPECIES SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

RATTUS; RODENTIA;

EID: 84872386643     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfs285     Document Type: Article

References (79)

1. Antonelli, A., Ferrari, S. M., Fallahi, P., Ghiri, E., Crescioli, C., Romagnani, P., Vitti, P., Serio, M., and Ferrannini, E. (2010a). Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: Modulation by peroxisome proliferator-activated receptor-gamma agonists. Cytokine 50, 260-267.
2. Antonelli, A., Ferrari, S. M., Frascerra, S., Pupilli, C., Mancusi, C., Metelli, M. R., Orlando, C., Ferrannini, E., and Fallahi, P. (2010b). CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J. Clin. Endocrinol. Metab. 95, E413-E420.
3. Armitage, P., and Doll, R. (1954). The age distribution of cancer and a multistage theory of carcinogenesis. Br. J. Cancer 8, 1-12.
4. Arozarena, I., Sanchez-Laorden, B., Packer, L., Hidalgo-Carcedo, C., Hayward, R., Viros, A., Sahai, E., and Marais, R. (2011). Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. Cancer Cell 19, 45-57.
5. Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000). Gene ontology: Tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25-29.
6. Baker, N. C., and Hemminger, B. M. (2010). Mining connections between chemicals, proteins, and diseases extracted from Medline annotations. J. Biomed. Inform. 43, 510-519.
7. Barter, R. A., and Klaassen, C. D. (1994). Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. Toxicol. Appl. Pharmacol. 128, 9-17.
8. Berenblum, I., and Shubik, P. (1947). A new, quantitative, approach to the study of the stages of chemical cartinogenesis in the mouse's skin. Br. J. Cancer 1, 383-391.
9. Berg, E. L., Kunkel, E. J., Hytopoulos, E., and Plavec, I. (2006). Characterization of compound mechanisms and secondary activities by BioMAP analysis. J. Pharmacol. Toxicol. Methods 53, 67-74.
10. Blackburn, J. S., Rhodes, C. H., Coon, C. I., and Brinckerhoff, C. E. (2007). RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 67, 10849-10858.
11. Capen, C. C. (1994). Mechanisms of chemical injury of thyroid gland. Prog. Clin. Biol. Res. 387, 173-191.
12. Cohen, S. M., and Arnold, L. L. (2011). Chemical carcinogenesis. Toxicol. Sci. 120(Suppl. 1), S76-S92.
13. Collins, F. S., Gray, G. M., and Bucher, J. R. (2008). Toxicology. Transforming environmental health protection. Science 319, 906-907.
14. Corton, J. C. (2010). Mode of action analysis and human relevance of liver tumors induced by PPARalpha activation. In Cancer Risk Assessment: Chemical Carcinogenesis, Hazard Evaluation, and Risk Quantification (C.-H. Hsu and T. Stedeford, Eds.) pp. 439-467. John Wiley & Sons, Hoboken, NJ.
15. Crofton, K. M. (2008). Thyroid disrupting chemicals: Mechanisms and mixtures. Int. J. Androl. 31, 209-223.
16. Crofton, K. M., and Zoeller, R. T. (2005). Mode of action: Neurotoxicity induced by thyroid hormone disruption during development-hearing loss resulting from exposure to PHAHs. Crit. Rev. Toxicol. 35, 757-769.
17. Dearfield, K. L. (1994). Ethylene thiourea (ETU). A review of the genetic toxicity studies. Mutat. Res. 317, 111-132.
18. Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R. W., and Kavlock, R. J. (2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95, 5-12.
19. Dragan, Y. P., Sargent, L., Xu, Y. D., Xu, Y. H., and Pitot, H. C. (1993). The initiation-promotion-progression model of rat hepatocarcinogenesis. Proc. Soc. Exp. Biol. Med. 202, 16-24.
20. Gerard, A. C., Boucquey, M., van den Hove, M. F., and Colin, I. M. (2006). Expression of TPO and ThOXs in human thyrocytes is downregulated by IL-1alpha/IFN-gamma, an effect partially mediated by nitric oxide. Am. J. Physiol. Endocrinol. Metab. 291, E242-E253.
21. Gittoes, N. J., and Franklyn, J. A. (1995). Drug-induced thyroid disorders. Drug Saf. 13, 46-55.
22. Goetz, A. K., and Dix, D. J. (2009). Toxicogenomic effects common to triazole antifungals and conserved between rats and humans. Toxicol. Appl. Pharmacol. 238, 80-89.
23. Gold, L. S., Manley, N. B., Slone, T. H., and Ward, J. M. (2001). Compendium of chemical carcinogens by target organ: Results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol. Pathol. 29, 639-652.
24. Greenfield, R. E., Ellwein, L. B., and Cohen, S. M. (1984). A general probabilistic model of carcinogenesis: Analysis of experimental urinary bladder cancer. Carcinogenesis 5, 437-445.
25. Guenzi, E., Topolt, K., Lubeseder-Martellato, C., Jorg, A., Naschberger, E., Benelli, R., Albini, A., and Sturzl, M. (2003). The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J. 22, 3772-3782.
26. Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and Weinberg, R. A. (1999). Creation of human tumour cells with defined genetic elements. Nature 400, 464-468.
27. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
28. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell 144, 646-674.
29. Hill, R. N., Crisp, T. M., Hurley, P. M., Rosenthal, S. L., and Singh, D. V. (1998). Risk assessment of thyroid follicular cell tumors. Environ. Health Perspect. 106, 447-457.
30. Houck, K. A., Dix, D. J., Judson, R. S., Kavlock, R. J., Yang, J., and Berg, E. L. (2009). Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen. 14, 1054-1066.
31. IARC. (1999). Species Differences in Thyroid, Kidney and Urinary Bladder Carcinogenesis, IARC Scientific Publication No. 147. International Agency for Research on Cancer, Lyon, France.
32. Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, Y., Dohi, K., Nakamura, N., and Akiyama, M. (1993). Genetic alterations in thyroid tumor progression: Association with p53 gene mutations. Jpn. J. Cancer Res. 84, 526-531.
33. Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. M., Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M., et al. (2010). In vitro screening of environmental chemicals for targeted testing prioritization: The ToxCast project. Environ. Health Perspect. 118, 485-492.
34. Judson, R., Richard, A., Dix, D., Houck, K., Elloumi, F., Martin, M., Cathey, T., Transue, T. R., Spencer, R., and Wolf, M. (2008). ACToR--Aggregated Computational Toxicology Resource. Toxicol. Appl. Pharmacol. 233, 7-13.
35. Kaminsky, D. E., and Rogers, T. J. (2008). Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes. J. Neuroimmune Pharmacol. 3, 75-82.
36. Kanehisa, M. (2002). The KEGG database. Novartis Found. Symp. 247, 91-101; discussion 101-103, 119-128, 244-252.
37. Kavlock, R. J., Austin, C. P., and Tice, R. R. (2009). Toxicity testing in the 21st century: Implications for human health risk assessment. Risk Anal. 29, 485-7; discussion 492-497.
38. Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003). PPARalpha agonist-induced rodent tumors: Modes of action and human relevance. Crit. Rev. Toxicol. 33, 655-780.
39. Kleinstreuer, N. C., Judson, R. S., Reif, D. M., Sipes, N. S., Singh, A. V., Chandler, K. J., Dewoskin, R., Dix, D. J., Kavlock, R. J., and Knudsen, T. B. (2011). Environmental impact on vascular development predicted by highthroughput screening. Environ. Health Perspect. 119, 1596-1603.
40. Knight, A. W., Little, S., Houck, K., Dix, D., Judson, R., Richard, A., McCarroll, N., Akerman, G., Yang, C., Birrell, L., et al. (2009). Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. Regul. Toxicol. Pharmacol. 55, 188-199.
41. Knudsen, T. B., Houck, K. A., Sipes, N. S., Singh, A. V., Judson, R. S., Martin, M. T., Weissman, A., Kleinstreuer, N. C., Mortensen, H. M., Reif, D. M., et al. (2011). Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets. Toxicology 282, 1-15.
42. Knudson, A. G. (1993). Antioncogenes and human cancer. Proc. Natl. Acad. Sci. U.S.A. 90, 10914-10921.
43. Knudson, A. G., Jr. (1971). Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 68, 820-823.
44. Kroll, T. G., Sarraf, P., Pecciarini, L., Chen, C. J., Mueller, E., Spiegelman, B. M., and Fletcher, J. A. (2000). PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science 289, 1357-1360.
45. Kuroda, T., Kitadai, Y., Tanaka, S., Yang, X., Mukaida, N., Yoshihara, M., and Chayama, K. (2005). Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin. Cancer Res. 11, 7629-7636.
46. Li, H., Lu, H., Griscelli, F., Opolon, P., Sun, L. Q., Ragot, T., Legrand, Y., Belin, D., Soria, J., Soria, C., et al. (1998). Adenovirus-mediated delivery of a uPA/ uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice. Gene Ther. 5, 1105-1113.
47. Lu, C., Zhao, L., Ying, H., Willingham, M. C., and Cheng, S. Y. (2010). Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology 151, 1929-1939.
48. Lund, E. (2011). An exposure driven functional model of carcinogenesis. Med. Hypotheses. 77, 195-198.
49. Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., et al. (2002). CYP3A4 induction by drugs: Correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos. 30, 795-804.
50. Mancina, R., Filippi, S., Marini, M., Morelli, A., Vignozzi, L., Salonia, A., Montorsi, F., Mondaini, N., Vannelli, G. B., Donati, S., et al. (2005). Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens. Mol. Hum. Reprod. 11, 107-115.
51. Martin, M. T., Dix, D. J., Judson, R. S., Kavlock, R. J., Reif, D. M., Richard, A. M., Rotroff, D. M., Romanov, S., Medvedev, A., Poltoratskaya, N., et al. (2010). Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem. Res. Toxicol. 23, 578-590.
52. Martin, M. T., Knudsen, T. B., Reif, D. M., Houck, K. A., Judson, R. S., Kavlock, R. J., and Dix, D. J. (2011). Predictive model of rat reproductive toxicity from ToxCast high throughput screening. Biol. Reprod. 85, 327-339.
53. Martin, M. T., Mendez, E., Corum, D. G., Judson, R. S., Kavlock, R. J., Rotroff, D. M., and Dix, D. J. (2009). Profiling the reproductive toxicity of chemicals from multigeneration studies in the toxicity reference database. Toxicol. Sci. 110, 181-190.
54. Matthews, L., Gopinath, G., Gillespie, M., Caudy, M., Croft, D., de Bono, B., Garapati, P., Hemish, J., Hermjakob, H., Jassal, B., et al. (2009). Reactome knowledgebase of human biological pathways and processes. Nucleic Acids Res. 37(Database issue), D619-D622.
55. McClain, J. (1999). A mechanistic relationship between thyroid follicular cell tumors and hepatocellular neoplasm in rodents. In Species Differences in Thyroid Gland, Kidney and Urinary Bladder Carcinogenesis, IARC Scientific Publications No. 147 (C. Capen, E. Dybing, J. Rice and J. Wilbourn, Eds.), pp. 61-68. IARC, Lyon, France.
56. Miller, M. D., Crofton, K. M., Rice, D. C., and Zoeller, R. T. (2009). Thyroiddisrupting chemicals: Interpreting upstream biomarkers of adverse outcomes. Environ. Health Perspect. 117, 1033-1041.
57. Moolgavkar, S. H., and Knudson, A. G., Jr. (1981). Mutation and cancer: A model for human carcinogenesis. J. Natl. Cancer Inst. 66, 1037-1052.
58. National Library of Medicine. (2011). Chemical Carcinogenesis Research Information System (CCRIS). Available at: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?ccrisadv.htm. Accessed June 27, 2011.
59. NRC. (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. National Academies Press, Washington, DC.
60. NTP. (2011). National Toxicology Program. Available at: http://ntp.niehs.nih.gov/. Accessed April 22, 2011.
61. Pacifico, F., and Leonardi, A. (2010). Role of NF-kappaB in thyroid cancer. Mol. Cell Endocrinol. 321, 29-35.
62. Pico, A. R., Kelder, T., van Iersel, M. P., Hanspers, K., Conklin, B. R., and Evelo, C. (2008). WikiPathways: Pathway editing for the people. PLoS Biol. 6, e184.
63. Rasmussen, A. K. (2000). Cytokine actions on the thyroid gland. Dan. Med. Bull. 47, 94-114.
64. Roca, H., Varsos, Z. S., Mizutani, K., and Pienta, K. J. (2008). CCL2, survivin and autophagy: New links with implications in human cancer. Autophagy 4, 969-971.
65. Romagnani, P., Lasagni, L., Annunziato, F., Serio, M., and Romagnani, S. (2004). CXC chemokines: The regulatory link between inflammation and angiogenesis. Trends Immunol. 25, 201-209.
66. Rotroff, D. M., Beam, A. L., Dix, D. J., Farmer, A., Freeman, K. M., Houck, K. A., Judson, R. S., LeCluyse, E. L., Martin, M. T., Reif, D. M., et al. (2010). Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J. Toxicol. Environ. Health B. Crit. Rev. 13, 329-346.
67. Rusyn, I., Peters, J. M., and Cunningham, M. L. (2006). Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit. Rev. Toxicol. 36, 459-479.
68. Sato, K., Satoh, T., Shizume, K., Ozawa, M., Han, D. C., Imamura, H., Tsushima, T., Demura, H., Kanaji, Y., and Ito, Y. (1990). Inhibition of 125I organification and thyroid hormone release by interleukin-1, tumor necrosis factor-alpha, and interferon-gamma in human thyrocytes in suspension culture. J. Clin. Endocrinol. Metab. 70, 1735-1743.
69. Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., and Buetow, K. H. (2009). PID: The Pathway Interaction Database. Nucleic Acids Res. 37(Database issue), D674-D679.
70. Simko, J., and Horacek, J. (2007). Carbamazepine and risk of hypothyroidism: A prospective study. Acta Neurol. Scand. 116, 317-321.
71. Sipes, N. S., Martin, M. T., Reif, D. M., Kleinstreuer, N. C., Judson, R. S., Singh, A. V., Chandler, K. J., Dix, D. J., Kavlock, R. J., and Knudsen, T. B. (2011). Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol. Sci. 124, 109-127.
72. Tinsley, H. N., Gary, B. D., Keeton, A. B., Zhang, W., Abadi, A. H., Reynolds, R. C., and Piazza, G. A. (2009). Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol. Cancer Ther. 8, 3331-3340.
73. Tinsley, H. N., Gary, B. D., Thaiparambil, J., Li, N., Lu, W., Li, Y., Maxuitenko, Y. Y., Keeton, A. B., and Piazza, G. A. (2010). Colon tumor cell growthinhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev. Res. (Phila). 3, 1303-1313.
74. U.S. EPA. (2010). EPA OPP List of Chemicals Evaluated for Carcinogenic Potential. Available at: http://www.epa.gov/pesticides/carlist/. Accessed January 24, 2012.
75. U.S. EPA. (2011). EPA ToxCast. Available at: http://www.epa.gov/ncct/toxcast/. Accessed May 23, 2011.
76. Ulisse, S., Baldini, E., Sorrenti, S., Barollo, S., Gnessi, L., Catania, A., Pellizzo, M. R., Nardi, F., Mian, C., De Antoni, E., et al. (2011). High expression of the urokinase plasminogen activator and its cognate receptor associates with advanced stages and reduced disease-free interval in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 96, 504-508.
77. Ündeǧer, Ü., and Başaran, N. (2005). Effects of pesticides on human peripheral lymphocytes in vitro: Induction of DNA damage. Arch. Toxicol. 79, 169-176.
78. Vansell, N. R., and Klaassen, C. D. (2001). Increased biliary excretion of thyroxine by microsomal enzyme inducers. Toxicol. Appl. Pharmacol. 176, 187-194.
79. Vicari, A. P., and Caux, C. (2002). Chemokines in cancer. Cytokine Growth Factor Rev. 13, 143-154.